[Immunology in clinical practice. XXIII. Xenotransplantation].
Currently xenotransplantation is being discussed on national and international levels as a possible solution to tranplantation waiting lists, in view of the lack of alternative therapies. In recent years, enormous progress has been made in the area of immunology, especially concerning hyperacute rejection. However, long-term survival is still fiction due to relatively unknown, sequential rejection processes. Moreover, it remains questionable if xenogeneic organs will function physiologically, especially if they are metabolically complex. A third problem is the possible infectious risk of xenotransplantation to the patient and the population. Regarding this hazard, various committees and policy reports demand clarity first before the initial clinical transplantations become fact. In the Netherlands, the government largely adopted an identical advice by the Health Council. Artificial organs and cloning developments indicate that xenotransplantation might merely be an intermediate station in the route to develop adequate treatment for patients with organ failure.
Schraa
E O
EO
Erasmus Universiteit, Laboratorium voor Experimentele Chirurgie en Oncologie, Rotterdam.
Marquet
R L
RL
Ijzermans
J N
JN
D000818:Animals; D006084:Graft Rejection / Q000276:immunology*; D006087:Graft vs Host Reaction / Q000276:immunology*; D006291:Health Policy; D006801:Humans; D009426:Netherlands; D014183:Transplantation, Heterologous / Q000009:adverse effects / Q000276:immunology* / Q000592:standards; D015047:Zoonoses / Q000635:transmission*
Immunologie in de medische praktijk. XXIII. Xenotransplantatie.